In vitro system based on patient´s immune cells to assist the selection of the best immunosuppression regimen for each patient, reducing risk of rejection and IMS side effects in a balanced manner.
- This model identifies drugs/doses/combined-therapies most able to damper the effector immune response and lymphocyte proliferation which causes rejection.
- This bioassay intends to help select the best personalized IMs therapy to keep the correct balance between rejection and IMs adverse events.
- It is a specific 3D cell culture such that enables a sensitive evaluation of IMs performance over patient´s immune cells proliferation and functioning.
- European patent has been presented in August 2016.